2650P Metastasis-directed therapies (MDT) for oligometastatic (OM) and oligoprogressive (OP) Renal Cell Cancer (RCC) patients with extra-lung metastases: The KAIROS study.
Saved in:
| Title: | 2650P Metastasis-directed therapies (MDT) for oligometastatic (OM) and oligoprogressive (OP) Renal Cell Cancer (RCC) patients with extra-lung metastases: The KAIROS study. |
|---|---|
| Authors: | Dimino, A.1 (AUTHOR), Rizzo, M.2 (AUTHOR), Fazio, I.3 (AUTHOR), Arcara, C.4 (AUTHOR), Mortellaro, G.5 (AUTHOR), Antonuzzo, L.6 (AUTHOR), Conteduca, V.7 (AUTHOR), Lipari, H.8 (AUTHOR), Sirgiovanni, G.9 (AUTHOR), Inguglia, S.10 (AUTHOR), Algeri, L.11 (AUTHOR), Spinnato, V.12 (AUTHOR), Cenzuales, D.13 (AUTHOR), Bracarda, S.14 (AUTHOR), Badalamenti, G.15 (AUTHOR), Porta, C.G.16 (AUTHOR), Russo, A.17 (AUTHOR), Incorvaia, L.18 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1420-S1420. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
